Results 21 to 30 of about 3,679,356 (272)

Pseudo-differentiation syndrome

Mediterranean Journal of Hematology and Infectious Diseases, 2011
A patient with relapsed acute myeloid leukemia (AML) (M2) FAB classification developed a differentiating syndrome upon receiving Decitabine therapy given with palliative intent.
Dina Khalaf, Fathi Jehani
doaj   +3 more sources

Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia

Blood Cancer Journal, 2023
TO THE EDITOR: Core binding factor acute myeloid leukemia (CBF-AML) features the recurrent chromosomal rearrangements t(8;21)(q22;22) and inv(16)(p13.1q22)/t(16;16)(p13.1;q22), which encode the RUNX1::RUNX1T1 and CBFB::MYH11 fusion genes; CBF-AML is ...
Keyuan Zhang, Xiang Zhang, Yang Xu, S. Xue, H. Qiu, Xiaowen Tang, Yue Han, Suning Chen, A. Sun, Yanming Zhang, Depei Wu, Ying Wang   +11 more
semanticscholar   +1 more source

Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies

Leukemia, 2021
Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA methylation, thereby triggering the re-programming of tumor cells.
Julia Stomper, J. Rotondo, G. Greve, M. Lübbert   +3 more
semanticscholar   +1 more source

Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings

Acta Medica Bulgarica, 2021
Introduction: Azacitidine is one of the hypomethylating agents available for the treatment of elderly patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
Nikolova D., Yordanov A., Radinov A.
doaj   +1 more source

Maintenance Therapy in AML

Frontiers in Oncology, 2021
Recent advances in therapeutics coupled with steady improvements in supportive care for patients with acute myeloid leukemia (AML) have led to improved outcomes.
Patrick K. Reville, Tapan M. Kadia
doaj   +1 more source

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach

Cancers, 2023
Simple Summary The hypomethylating agents (HMA) azacitidine and decitabine are among the standard treatment options for myeloid neoplasms. However, the treatment of patients with myelodysplastic syndromes/neoplasms (MDS) and acute myeloid leukemia (AML ...
H. Awada, C. Gurnari, Zhuoer Xie, J. Bewersdorf, A. Zeidan   +4 more
semanticscholar   +1 more source

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia

Therapeutic Advances in Hematology, 2021
In recent years, one of the most successful advances in treating acute myeloid leukaemia (AML) has been the combination of the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax with hypomethylating agents (decitabine or azacytidine).
Nerea Báez-Gutiérrez, Héctor Rodríguez-Ramallo, María Antonia-Pérez Moreno, Eduardo-Rodriguez Arboli, Laila Abdel-kader Martín   +4 more
doaj   +1 more source

Blastic plasmacytoid dendritic cell neoplasm: Genomics mark epigenetic dysregulation as a primary therapeutic target [PDF]

, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy for which there is still no effective B therapy.
Abate F., Agostinelli C., Amente S., Berti E., Bertolini F., Brundu F., Cerroni L., Dellino G. I., Etebari M., Facchetti F., Falini B., Fuligni F., Indio V., Laginestra M. A., Melle F., Motta G., Orecchioni S., Paulli M., Piccioni R., Pileri A., Pileri S. A., Pimpinelli N., Rabadan R., Rossi M., Sabattini E., Sapienza M. R., Tabanelli V., Talarico G., Tarantino G., Tripodo C., Truni M.   +30 more
core   +2 more sources

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.

Blood Advances, 2021
Hypomethylating agents (HMAs) are widely used in the treatment of myelodysplastic syndromes (MDSs), yet identifying those patients unlikely to benefit remains challenging.
A. Hunter, R. Komrokji, Seongseok Yun, N. Al Ali, O. Chan, Jinming Song, M. Hussaini, Chetasi Talati, K. Sweet, J. Lancet, E. Padron, A. List, D. Sallman   +12 more
semanticscholar   +1 more source